Every 10-Q that Procter & Gamble Company (PG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PG filings page.
The Procter & Gamble Company (PG) reported net sales of $23.276 billion for the three months ended September 30, 2026, up 4% from $22.386 billion a year earlier. Net earnings were $4.757 billion, down 1%, while diluted earnings per share rose 1% to $1.97. Operating cash flow increased $359 million to $5.767 billion; free cash flow was $4.401 billion. Net sales increased across all five reporting segments, from 3% in Health Care and Baby, Feminine & Family Care to 6% in Beauty.
Gross margin declined 160 basis points to 49.8%, as higher commodity costs and product and packaging investments were partly offset by productivity savings. P&G incurred $192 million of restructuring charges during the quarter under a plan expecting approximately $2.0 billion in before-tax costs over two years and up to 7,000 non-manufacturing overhead reductions by the end of fiscal 2027. On October 1, 2026, P&G completed its $3.9 billion all-cash acquisition of Thorne, which will join Personal Health Care; its results are not material to P&G. The company expects to reduce outstanding shares through direct share repurchases at a value of approximately $5.0 billion in fiscal year 2027.
Procter & Gamble reported higher sales and earnings for the March 31, 2026 quarter and nine-month period. Quarterly net sales rose to $21.2 billion from $19.8 billion, with organic sales up 3% on modest volume growth, pricing and favorable foreign exchange.
Quarterly net earnings attributable to Procter & Gamble increased to $3.9 billion, and diluted EPS grew to $1.63 from $1.54. For the nine months, net sales reached $65.8 billion and net earnings attributable to Procter & Gamble were $13.0 billion, driving diluted EPS of $5.36 and Core EPS of $5.46.
Gross margin declined on mix, product and packaging investments, tariffs and higher restructuring, partly offset by productivity savings. Operating cash flow was $14.4 billion, with adjusted free cash flow of $11.7 billion and adjusted free cash flow productivity of 92%. The company is executing a $1.5–$2.0 billion restructuring plan and recorded a gain from dissolving the Glad joint venture, while noting potential recovery of about $200 million in previously paid U.S. tariffs.
The Procter & Gamble Company reports steady results for the three and six months ended December 31, 2025, with modest sales growth but some margin pressure. For the three-month period, net sales rose to $22.2 billion from $21.9 billion (up about 1%), while net earnings declined to $4.3 billion from $4.7 billion and diluted EPS slipped to $1.78 from $1.88 as gross margin and operating margin narrowed due to unfavorable mix, higher tariffs, product and packaging investments and higher restructuring costs.
Over six months, net sales increased to $44.6 billion from $43.6 billion (2% growth), net earnings rose to $9.1 billion from $8.6 billion (5% growth) and diluted EPS grew 7% to $3.73. Core EPS, which excludes incremental restructuring, was $3.87, up 2%. Operating margin eased to 25.2% as higher restructuring and tariff costs outweighed productivity savings and pricing. Operating cash flow reached $10.4 billion, with adjusted free cash flow of $8.7 billion and adjusted free cash flow productivity of 95%, while the company continued significant restructuring and recorded strong contributions from Beauty, Grooming and Health Care segments.
The Procter & Gamble Company reported first‑quarter results for the three months ended September 30, 2025. Net sales were $22.4 billion, up 3% year over year, driven by 1% pricing, 1% mix and 1% favorable foreign exchange. Operating income was $5.9 billion (up 1%), while gross margin was 51.4% (down 70 bps) and operating margin was 26.2% (down 50 bps).
Net earnings rose 20% to $4.8 billion, and diluted EPS increased 21% to $1.95, reflecting the prior year’s Argentina-related charges. Operating cash flow was $5.4 billion; capital expenditures were $1.2 billion; adjusted free cash flow was $4.9 billion with 102% productivity. The company paid $2.55 billion in dividends and repurchased $1.25 billion of stock.
By segment, net sales grew in Beauty (+6%), Grooming (+5%), Health Care (+2%), Fabric & Home Care (+1%) and Baby, Feminine & Family Care (+1%). P&G incurred $215 million in restructuring charges as part of its two‑year $1.5–$2.0 billion productivity plan. The Glad joint venture will not be renewed; P&G expects about $500 million of proceeds and a $250–$300 million after‑tax gain in the third quarter of fiscal 2026. Shares outstanding were 2,336,733,549 as of September 30, 2025.